Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 415-422

  Ou, Sai Hong I ^a   Janne P A ^b   Bartlett, C H ^c   Tang, Y ^d   Kim, D W ^e   Otterson, G A ^f   Crino L ^g   Selaru, P ^d   Cohen, D P ^d   Clark, J W ^b   Riely, G J ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Pfizer Ltd   (United States)

^d Pf Izer Oncology Inc   (United States)

^e Seoul National University Hospital   (South Korea)

^f OHIO STATE UNIVERSITY   (United States)

^g SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

ALK positive NSCLC; Crizotinib; Oncogene addiction; RECIST; TKI; Treatment beyond disease progression

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; CRIZOTINIB BEYOND DISEASE PROGRESSION; DRUG EFFICACY; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; ENZYMOLOGY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROPORTIONAL HAZARDS MODELS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893399587     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt572     Document Type: Article

References (25)

1. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
2. Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190-1203.
3. Ou SH, Bartlett CH, Mino-Kenudson M et al. Crizotinib for the treatment of ALKrearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012; 17: 1351-1375.
4. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
5. Kim DW, Ahn MJ, Shi Y et al. Results of a global phase II study with crizotinib in ALK-positive non-small cell lung cancer NSCLC. J Clin Oncol 2012; 30(Suppl): abstr 7533.
6. Shaw AT, Kim DY, Nagakawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
7. Riely GJ, Kris MG, Zhao B et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007; 13: 5150-5155.
8. Nishie K, Kawaguchi T, Tamiya A et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol 2012; 7: 1722-1727.
9. Chaft JE, Oxnard GR, Sima CS et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011; 17: 6298-6303.
10. Pop O, Pirvu A, Toffart AC et al. Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib. J Thorac Oncol 2012; 7: e1-e2.
11. Camidge DR, Bang YJ, Kwak EL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-1019.
12. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009; 27: 1999-2006.
13. von Minckwitz G, Schwedler K, Schmidt M et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 2011; 47: 2273-2281.
14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology; Non-Small Cell Lung Cancer, v.2. 2013; June 2013, date last accessed.
15. Heuckmann JM, Balke-Want H, Malchers F et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 2012; 18: 4682-4690.
16. Choi YL, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363: 1734-1739.
17. Katayama R, Shaw AT, Khan TM et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012; 4: 120ra17.
18. Sasaki T, Koivunen J, Ogino A et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011; 71: 6051-6060.
19. Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012; 18: 1472-1482.
20. Weickhardt AJ, Scheier B, Burke JM et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012; 7: 1807-1814.
21. Browning ET, Weickhardt AJ, Camidge DR. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer. J Thorac Oncol 2013; 8: e21.
22. Sang J, Acquaviva J, Friedland JC et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 2013; 3: 430-443.
23. Camidge DR, Bazhenova L, Salgia R et al. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: updated results. J Clin Oncol 2013; 31(Suppl): abstr 8031.
24. Shaw AT, Mehra R, Kim DW et al. Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. J Clin Oncol 2013; 31(Suppl): abstr 8010.
25. Ou S, Gadgeel S, Chiappori A et al. Safety and efficacy analysis of RO5424802/ CH5424802 in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients who have failed crizotinib in a dose-finding phase I study (AF-002JG, NCT01588028). Eur J Cancer 2013; 49(Suppl 2): LBA44.